



## Protection of *Procambarus clarkii* against white spot syndrome virus using inactivated WSSV

Fei Zhu<sup>a</sup>, Huahua Du<sup>a</sup>, Zhi-Guo Miao<sup>b</sup>, Hai-Zhi Quan<sup>a</sup>, Zi-Rong Xu<sup>a,\*</sup>

<sup>a</sup> Key Laboratory of Molecular Animal Nutrition, Ministry of Education, Feed Science Institute, Zhejiang University, Hangzhou 310029, PR China

<sup>b</sup> School of Animal Science, Henan Institute of Science and Technology, XinXiang 453003, PR China

### ARTICLE INFO

#### Article history:

Received 1 January 2009

Received in revised form

5 February 2009

Accepted 21 February 2009

Available online 4 March 2009

#### Keywords:

White spot syndrome virus

*Procambarus clarkii*

Vaccination

BEI

Inactivate

### ABSTRACT

White spot syndrome virus (WSSV) is a highly pathogenic and prevalent virus infecting shrimp and other crustaceans. The potentiality of binary ethylenimine (BEI)-inactivated WSSV against WSSV in crayfish, *Procambarus clarkii*, was investigated in this study. Efficacy of BEI-inactivated WSSV was tested by vaccination trials followed by challenge of crayfish with WSSV. The crayfish injected with BEI-inactivated WSSV showed a better survival ( $P < 0.05$ ) to WSSV on the 7th and 21st day post-vaccination (dpv) compared to the control. Calculated relative percent survival (RPS) values were 77% and 60% on the 7th and 21st dpv for 2 mM BEI-inactivated WSSV, and 63%, 30% on 7th and 21st dpv for 3 mM BEI-inactivated WSSV. However, heat-inactivated WSSV did not provide protection from WSSV even on 7th dpv. In the inactivation process WSSV especially their envelope proteins maybe changed as happened to 3 mM BEI and heat-inactivated WSSV particles. These results indicate the protective efficacy of BEI-inactivated WSSV lies on the integrity of envelope proteins of WSSV and the possibility of BEI-inactivated WSSV to protect *P. clarkii* from WSSV.

© 2009 Elsevier Ltd. All rights reserved.

### 1. Introduction

Electron microscopy (EM) showed that white spot syndrome virus (WSSV) is enveloped, bacilliform in shape and have a tail-like appendage at one end [1]. The virus contains double stranded DNA with an estimated size of 292967 bp, with 181 open reading frames consisting of 39 structural proteins [2–4]. However, different genome sizes have been reported from diverse virus isolates and large genome sequences have been reported from virus isolates from China and Thailand [5]. White spot syndrome virus has a broad host range within Decapoda crustaceans, including penaeid shrimp and crayfish [6–8]. White spot syndrome virus (WSSV) belongs to the new virus family *Nimaviridae*, genus *Whispovirus* [9]. In China, production losses of 80% of farmed shrimp were attributed to WSSV [10,11].

Crustaceans do not possess an adaptive immune system, but now it is doubted for some investigation [12,13]. A recent study in vaccinated crayfish surviving from experimental WSSV infections showed that it possess a resistance against WSSV [14–18]. Of the viral structural proteins, envelope proteins often play vital roles in

virus entry and assembly [19–21]. Vaccination using viral proteins, especially VP28, has been reported to offer shrimp protection against WSSV infection [22–24]. However, a neutralization assay with the combination of antibodies against different envelope proteins showed that a combination of VP36B and VP31 antibodies could strongly inhibit WSSV infection in crayfish. It revealed that multiple envelope proteins are involved in WSSV infection in crayfish during this process [25].

Furthermore, immunostimulation of shrimp with inactivated vibrio have been reported to provide some protection [26]. The shrimp intramuscularly vaccinated with formalin-inactivated WSSV can induce a resistance to the virus of intramuscular (IM) injection on the 10th day post-vaccination [27]. These reports suggest that some of envelope proteins can induce an immune response and protect shrimp against WSSV. Thus inactivated WSSV will be a good vaccine to shrimp but inactivating with formalin and heat are not good method. Binary ethylenimine (BEI) is a kind of aziridines and formed by the cyclization of 2-chloroethylamine hydrochloride (BEA). BEI is known to alkylate nucleic acids but do not damage the protein of inactivated virus in the concentration of 1 mM [28,29]. In veterinary medicine BEI is the preferred inactivating agent for producing vaccines containing animal viruses with DNA or RNA genomes [30–32]. Although chemical agents and physical methods have been studied on the inactivation of WSSV

\* Corresponding author. Tel.: +86 571 8609 1820; fax: +86 571 8699 4963.

E-mail address: [zrxu@zju.edu.cn](mailto:zrxu@zju.edu.cn) (Z.-R. Xu).

[33,34], but envelope proteins of inactivated virus was damaged when WSSV was inactivated. Our study was carried out to explore the possibility of protecting *Procambarus clarkii* from WSSV infection by vaccination with BEI-inactivated WSSV.

## 2. Materials and methods

### 2.1. Crayfish

Crayfish *P. clarkii*, approximately 20 g and 8 cm each, were reared at  $25 \pm 1$  °C. They were kept in tanks with sand-filtered, ozone-treated and flow-through freshwater and fed with commercial pellet feed at 5% of body weight per day. Walking legs from randomly selected individuals were subjected to PCR assays to ensure that the crayfish were WSSV-free before experimental challenge.

### 2.2. Measurement of viral infectivity ( $LD_{50}$ )

The infectivity (lethal dose 50%:  $LD_{50}$ ) of WSSV was used as the criterion for the virus inactivation tests. White spot syndrome virus-infected shrimp, *Fennerpenaeus chinensis*, were collected from shrimp farms located near Ningbo, China. Ten grams of infected tissues (gills and tail muscle) were homogenized in 500 ml TNE buffer (50 mM Tris-HCl, 400 mM NaCl, 5 mM EDTA, pH 7.5) containing a combination of protease inhibitors (1 mM phenyl-methylsulphonyl fluoride (PMSF), 1 mM benzamidine, and 1 mM  $Na_2S_2O_5$ ), and then centrifuged at  $10,000 \times g$  for 10 min at 4 °C. After filtering by nylon net (400 mesh), this homogenate was centrifuged at  $6000 \times g$  for 25 min at 4 °C and filtrated using a Millipore filter (pore size 0.45  $\mu$ m). This filtrate was the original viral fluid that was used for the inactivation tests afterwards. To measure the infectivity of this virus fluid, 10-fold serial dilutions of the fluid were made from  $10^4$  to  $10^9$  and filtrated using a Millipore filter (pore size 0.45  $\mu$ m). These diluted fluids were injected into each of 30 healthy crayfish (average body weight 20.0 g) at the dose of 0.1 mL/crayfish. Mortality and clinical signs were observed daily for two weeks.

### 2.3. Inactivated WSSV

0.2 M binary ethylenimine (BEI) was prepared by cyclization of 0.2 M 2-bromoethylamine-HBr in 0.2 M NaOH at 37 °C for 1 h. The  $\beta$ -naphthol violet (a pH indicator) was added to the solution to check the formation of BEI which causes a change in colour from violet to orange. This solution was added to  $10^1$  WSSV dilution as 1:100 (v/v) to a concentration of 2 mM. The solution was incubated at 37 °C with continuous stirring for 6 h, 12 h, 18 h, 24 h and the reaction was stopped by addition of sodium thiosulphate. And 0.3 M BEI solution prepared by the same way was added to 10 diluted WSSV solution to a concentration of 3 mM and incubated at 37 °C with continuous stirring for 24 h and the reaction was stopped by addition of sodium thiosulphate.

For preparation of heat-inactivated WSSV, the viral suspension was diluted 10-fold in TNE and inactivated for 15 min at 65 °C.

For in vivo injection experiment the healthy crayfish collected from stock were divided into nine groups (30 crayfish per group per tank). For test the safety of BEI and heat-inactivated WSSV six groups of 30 crayfish were intramuscularly (IM) injected with 0.1 mL inactivated WSSV solution. A group of 30 crayfish was IM injected with 0.1 mL of WSSV (10 dilution) which were heated at 37 °C for 24 h to test its effects on WSSV. The positive control groups were injected with 0.1 mL of WSSV (10 dilution) and the negative control was injected with 0.1 mL of TNE solution (Table 1).

**Table 1**

Effect of BEI and various temperature tested on WSSV infectivity in *Procambarus clarkii*.

Group	Treatment	Dead/tested	Mortality (%)
2 mM BEI			
1	37 °C/6 h	30/30	100
2	37 °C/12 h	30/30	100
3	37 °C/18 h	27/30	90
4	37 °C/24 h	0/30	0
3 mM BEI	37 °C/24 h	0/30	0
37 °C	37 °C/24 h	30/30	100
65 °C	65 °C/15 min	0/30	0
Positive control	–	30/30	100
Negative control	–	0/30	0

No mortality indicated WSSV was inactivated completely and this treatment could be used to produce vaccine.

### 2.4. Electron microscopy and SDS-PAGE

BEI-inactivated WSSV and heat-inactivated WSSV particles were negatively stained with 2% sodium phosphotungstate (PTA, pH 7.0) on collodion-carbon coated grids. All observations were made with a JEOL 1230 transmission electron microscope (JEOL, Japan) operating at 70 kV. The two kinds of inactivated WSSV were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli [35]. The gels were stained with Coomassie brilliant blue (0.1% Coomassie Blue R-250 in 1% acetic acid and 40% methanol). A premixed protein molecular weight marker (Fermentas), with proteins ranging from 14.4 to 116 kDa, was co-electrophoresed to determine the molecular weights of the WSSV proteins.

### 2.5. PCR analysis for WSSV

Total DNA was extracted from walking legs of crayfish with an animal tissue genomic DNA mini-prep kit (Sangon, Shanghai). The samples were tested with one primer set VP28-FW (5'-CGCACA GACAATATCGAGAC-3') and VP28-RV (5'-GTCTCAGTGCCAGAGTAG GT-3'), amplifying part of WSSV VP28 gene, was used to screen for WSSV-positive animals. PCR was performed with the VP28 primer pair using the following protocol: 5 min at 94 °C followed by 35 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min. The PCR products were analyzed by electrophoresis on 1% agarose gels stained with ethidium bromide and visualized by ultraviolet transilluminator.

### 2.6. Vaccination experiments

For vaccination experiment 12 groups of 30 inter-molt crayfish with an average weight of 20 g were selected. Before starting the vaccination experiment the crayfish were tested for the presence of WSSV by one step PCR. Six groups of crayfish were vaccinated by IM injection with 0.1 mL of 2mM BEI, 3mM BEI and heat-inactivated WSSV and the controls were IM injected with 0.1 mL of 2mM BEI, 3mM BEI and TNE solution. Seven days after the initial vaccination, three groups and their control groups were IM injected with 0.1 mL of WSSV dilution ( $1 \times 10^7$ ) for the challenge test. Another three groups and their control groups were challenged by the same way at 21st day post-vaccination (dpv) (Table 2).

### 2.7. Statistical analysis

The mortalities of the tested and control groups were compared statistically using the chi-square test ( $\chi^2$ ) at a significance level of 5%. The relative percent survival (RPS) values were calculated

**Table 2**

Resistance against experimental WSSV infection in *Procambarus clarkii* vaccinated with BEI or heat-inactivated WSSV.

Time of challenge	Dead/tested	Mortality (%)	RPS (%)	P-value
7 dpv				
2 mM BEI-inactivated WSSV	7/30	23	77	0.000*
Control	30/30	100		
3 mM BEI-inactivated WSSV	11/30	37	63	0.000*
Control	30/30	100		
Heat-inactivated WSSV	27/30	90	10	0.609
Control	30/30	100		
21 dpv				
2 mM BEI-inactivated WSSV	12/30	40	60	0.000*
Control	30/30	100		
3 mM BEI-inactivated WSSV	21/30	70	30	0.021*
Control	30/30	100		
Heat-inactivated WSSV	29/30	97	3	0.831
Control	30/30	100		

Control group crayfish were injected with TNE solution mixed with BEI or not. Significant difference (5% level) compared with the corresponding unvaccinated group is indicated by \*.

according to Amend [36]. Cumulative mortalities, RPS values and *P*-values were determined at the termination (24th day) of challenge test made seven days after the last vaccination.

### 3. Results

#### 3.1. Measurement of viral infectivity ( $LD_{50}$ )

The results of viral infectivity ( $LD_{50}$ ) as measured by the mortality of injected crayfish showed 100% in all test groups until  $10^7$  of the serial dilutions, but showed 55% for the  $10^8$  dilution group. Therefore, the  $LD_{50}$  value of the original viral fluid was estimated to be  $10^8$  dilution. So we used  $1 \times 10^7$  dilution of WSSV as the challenge dose in the challenge test.

#### 3.2. Inactivation of WSSV

IM injection experiment showed that WSSV had been inactivated by BEI completely and the solution was safety for oral vaccination (Table 1). 2 mM BEI resulted in mortalities of 100% in 6 and 12 h, 90% in 18 h and 100% in 24 h. The result reveals that BEI can inactivate WSSV in temperature of 37 °C and the proper concentration of 2 mM and 3 mM BEI also inactivated WSSV completely. No mortality was recorded in the negative control and the positive control resulted in mortalities of 100% on the 17th day. The cumulative mortalities in the 37 °C heated WSSV group indicated WSSV could keep the infectivity even exposed to 37 °C over 24 h. So only BEI as the inactivant contributes to the completely inactivation of WSSV. WSSV could be completely inactivated by either 20 min exposure to 60 °C or 10 min exposure to 70 °C, but WSSV was not inactivated by even 30 min exposure to 50 °C [33]. Although aquatic viruses receive thermal protection from the natural aqueous environment as water temperature is seldom higher than 35 °C, WSSV showed a resistance to high temperature under 60 °C and the resistance is as stronger as in lower temperature. In this study, WSSV could be completely inactivated by 65 °C for 15 min.

#### 3.3. Electron microscopy

The TEM microphotograph showed that the envelopes of 2 mM and 3 mM BEI-inactivated WSSV seem to have a little changed compared with the purified WSSV (Fig. 1), but the virus particles are intact basically. But the envelope of WSSV was destroyed badly and the nucleocapsid was exposed to the outer in heat-inactivated WSSV (Fig. 1).

#### 3.4. SDS-PAGE analysis

The SDS-PAGE analysis showed that more than ten bands in the purified WSSV and 2 mM BEI-inactivated WSSV, but only five bands in the 3 mM BEI-inactivated WSSV (Fig. 2). In the purified WSSV and 2 mM BEI-inactivated WSSV, the bands of VP15, VP19, VP28 and VP281 obviously exist. In 3 mM BEI-inactivated WSSV only the bands of VP26 and VP28 were obvious. No protein was found in linear heat-inactivated WSSV (Fig. 2).

#### 3.5. Vaccination experiment

The time–mortality relationships in the vaccination experiment are shown in Fig. 3. The cumulative mortality percentage (CMP) of the groups vaccinated with 2 mM BEI, 3 mM BEI, and heat-inactivated WSSV and challenged at 7 dpv was 23%, 37% and 90% respectively (Table 2, Fig. 3a). Calculated RPS values were 77%, 63% and 10% for the groups vaccinated with 2 mM BEI, 3 mM BEI, and heat-inactivated WSSV (Table 2). Significantly lower mortality ( $P < 0.05$ ) in the 2 mM BEI-inactivated WSSV (23%) and 3 mM BEI-inactivated WSSV (37%) vaccinated group compared with its control group (100%). But no significant differences in cumulative mortalities were observed between the groups injected with heat-inactivated WSSV and its control group.

The CMP of the groups vaccinated with 2 mM BEI, 3 mM BEI, and heat-inactivated WSSV vaccinated groups challenged at 21 dpv were 40%, 70% and 97% respectively (Table 2, Fig. 3b). Calculated RPS values were 60%, 30% and 3% for the groups vaccinated with 2 mM BEI, 3 mM BEI, and heat-inactivated WSSV (Table 2). Significantly lower mortalities ( $P < 0.05$ ) were observed in the 2 mM BEI-inactivated WSSV (40%) and 3 mM BEI-inactivated WSSV (70%) vaccinated group compared with its control group (100%).


### 4. Discussion

Recently various agents, i.e. inactivated WSSV, antibacterial components, and subunit recombinant envelope proteins tried so far against WSSV have shown encouraging results [14–18,22–24,27,37,38]. Now more and more report indicated that envelope proteins, especially VP28, could offer shrimp protection against WSSV infection [22–25]. In this investigation we found that the protection efficacy of inactivated WSSV is dependent on the integrity of envelope proteins as previous report in the vaccination trial of veterinary virus [30,32,39,40]. We also found that the protection will decrease along with day after last vaccination like previous reports [23,27].


The Electron microscopy showed that maybe the envelope of WSSV is changed a little in 2 mM and 3 mM BEI (Fig. 1). And the SDS-PAGE analysis indicated that higher than 2 mM concentration of BEI may change the envelope proteins of WSSV more (Fig. 2). The loss of envelope protein in 3 mM BEI-inactivated WSSV may explain the significant difference among the RPS of 2 mM BEI, and heat-inactivated WSSV. Because envelope proteins have been confirmed that could protect the crustaceans against WSSV. In this study, we think that 2 mM BEI can inactivate WSSV completely and preserve the integrity of envelope proteins in optimum. The significant differences ( $P < 0.05$ ) between BEI and heat-inactivated WSSV maybe explained by the loss of envelope proteins, which provided the protection against WSSV.

No mortality was recorded in vaccinated crayfish before the challenge test indicated that the inactivated WSSV vaccine was safety for vaccine crayfish as confirmed in the inactivation experiment. The challenge test made on the 7th and 21st dpv resulted in significantly lower mortality ( $P < 0.05$ ) in the 2 mM and 3 mM BEI-inactivated WSSV vaccinated group compared with its control






**Fig. 1.** Electron microscopic view of negatively stained, normal WSSV particle (A), 2 mM BEI-inactivated WSSV particle (B), 3 mM BEI-inactivated WSSV particle (C) and heat-inactivated WSSV (D). (A. bar = 200 nm; B–D. bar = 100 nm).



**Fig. 2.** Fifteen percent Coomassie brilliant blue-stained SDS-PAGE gel of purified WSSV and BEI-inactivated WSSV. Lane 1. Purified WSSV. Lane 2. Protein marker (14.4 kDa, 18.4 kDa, 25 kDa, 35 kDa, 45 kDa, 66.2 kDa and 116.0 kDa). Lane 3. 2 mM BEI-inactivated WSSV. Lane 4. 3 mM BEI-inactivated WSSV. Lane 5. Heat-inactivated WSSV.

group (100%). However, the RPS on 21st dpv showed a significant difference between 2 mM and 3 mM BEI-inactivated WSSV. The difference may be examined by the damages in the envelope proteins of WSSV that showed in Electron microscopy and SDS-PAGE. Electron microscopy showed that a little damage happened to the envelope proteins of WSSV in 2 mM and 3 mM BEI-inactivated WSSV but heat at 65 °C for 15 min destroyed the envelope proteins completely (Fig. 2). The analysis of SDS-PAGE indicated that in the linear of 3 mM BEI-inactivated WSSV the band of VP28 was not obvious and the band of VP15, VP19 and VP281 could not be found compared within the linear of 2 mM BEI-inactivated WSSV. The envelope of heat-inactivated WSSV particle was destroyed may explained that no proteins was found in the linear of heat-inactivated WSSV (Fig. 1d, Fig. 2). The high cumulative mortality in the heat-inactivated WSSV vaccinated group indicated that heat-inactivated WSSV did not provide a protection from WSSV, and Namikoshi et al. also reported the same result [27]. So we think that the protection provided by inactivated WSSV is dependent on the integrity of envelope proteins of WSSV.

Our results showed that vaccinating crayfish with BEI-inactivated WSSV would protect the crayfish against WSSV seven days after the last vaccination. Crayfish *P. clarkii* is susceptible to WSSV as penaeid shrimp and WSSV caused more than 90% mortality in crayfish through oral challenge and IM injection [15]. Crayfish injected with 3 mM BEI-inactivated WSSV showed no bad signs and



**Fig. 3.** Time-mortality relationship of experiment 1. Juvenile crayfish were vaccinated inactivated WSSV followed by viral challenge at (A) 7 days and (B) 21 days post-vaccination. Cumulative mortality rates of shrimp from the experimental groups, as indicated in Table 2 are plotted against time (18-day period) after challenge.

be active like normal crayfish in this study. We believe that vaccination with

BEI-inactivated WSSV was successful in protecting crayfish against WSSV, similar findings were also obtained by Namikoshi et al. using formalin-inactivated WSSV [27]. In conclusion, crayfish can be induced a resistance to WSSV by BEI-inactivated WSSV, but BEI in concentration of above 2 mM will damage the envelope proteins of WSSV and reduce the protective efficacy of BEI-inactivated WSSV. These results confirm that the protective efficacy of vaccine made of BEI-inactivated WSSV lies on the integrity of envelope proteins of WSSV and reveal the possibility of vaccination of *P. clarkii* with BEI-inactivated WSSV.

## Acknowledgements

The authors thank the management of Feed Science Institute, Zhejiang University for providing the facilities to carryout this work. We also appreciate Jian Hong, Linlin Fu for their valuable advice. This research was supported by the Planned Science and Technology Project of Zhejiang Province, China (No. 2008C32034).

## References

- [1] Escobedo Bonilla CM, Alday Sanz V, Wille M, Sorgeloos P, Pensaert MB, Nauwynck HJ. A review on the morphology, molecular characterization, morphogenesis and pathogenesis of white spot syndrome virus. *J Fish Dis* 2008;31:1–18.
- [2] Yang F, He J, Lin X, Li Q, Pan D, Zhang X, et al. Complete genome sequence of the shrimp white spot bacilliform virus. *J Virol* 2001;75:11811–20.
- [3] van Hulten MCW, Witteveldt J, Peters S, Kloosterboer N, Tarchini R, Fiers M. The white spot syndrome virus DNA genome sequence. *Virology* 2001;286:7–22.
- [4] van Hulten MCW, Goldbach RW, Vlask JM. Three functionally diverged major structural proteins of white spot syndrome virus evolved by gene duplication. *J Gen Virol* 2000;81:2525–9.
- [5] Marks H, Goldbach RW, Vlask JM, van Hulten MCW. Genetic variation among isolates of white spot syndrome virus. *Arch Virol* 2003;149:673–97.

- [6] Wang YC, Lo CF, Chang PS, Kou GH. Experimental infection of white spot baculovirus in some cultured and wild decapods in Taiwan. *Aquaculture* 1998;164:221–31.
- [7] Lo CF, Ho CH, Peng SE, Chen CH, Hsu HC, Chiu YL. White spot syndrome baculovirus (WSBV) detected in cultured and captured shrimp, crabs and other arthropods. *Dis Aquat Org* 1996;27:215–25.
- [8] Jiravanichpaisal P, Bangyeekhun E, Soderhall K, Soderhall I. Experimental infection of white spot syndrome virus in freshwater crayfish *Pacifastacus leniusculus*. *Dis Aquat Org* 2001;47:151–7.
- [9] Mayo MA. A summary of taxonomic changes recently approved by ICTV. *Arch Virol* 2002;147:1655–6.
- [10] Chen X, Chen P, Wu D. Study on a new bacilliform virus in cultured shrimps. *Sci China Ser* 1997;C27:415–20.
- [11] Zhan WB, Wang YH, Fryer JL, Yu KK, Fukuda H, Meng QX. White spot syndrome virus infection of cultured shrimp in China. *J Aquat Anim Health* 1998;10:405–10.
- [12] Arala Chaves M, Sequeira T. Is there any kind of adaptive immunity in invertebrates? *Aquaculture* 2000;191:247–58.
- [13] Kurtz J, Franz K. Innate defence: evidence for memory in invertebrate immunity. *Nature* 2003;425:37–8.
- [14] Du HH, Xu ZR, Wu XF, Li WF, Dai W. Increased resistance to white spot syndrome virus in *Procambarus clarkii* by injection of envelope protein VP28 expressed using recombinant baculovirus. *Aquaculture* 2006;260:39–43.
- [15] Jha RK, Xu ZR, Bai SJ, Sun JY, Li WF, Shen J. Protection of *Procambarus clarkii* against white spot syndrome virus using vaccine expressed in *Pichia pastoris*. *Fish Shellfish Immunol* 2006;22:295–307.
- [16] Jha RK, Xu ZR, Shen J, Bai SJ, Sun JY, Li WF. The efficacy of recombinant vaccines against white spot syndrome virus in *Procambarus clarkii*. *Immunol Lett* 2006;105:68–76.
- [17] Xu ZR, Du HH, Xu YX, Sun JY, Shen J. Crayfish *Procambarus clarkii* protected against white spot syndrome virus by oral administration of viral proteins expressed in silkworms. *Aquaculture* 2006;253:179–83.
- [18] Fu LL, Li WF, Du HH, Dai W, Xu ZR. Oral vaccination with envelope protein VP28 against white spot syndrome virus in *Procambarus clarkii* using *Bacillus subtilis* as delivery vehicles. *Lett Appl Microbiol* 2008;46:581–6.
- [19] van Hulten MCW, Witteveldt J, Snippe M, Vlask JM. White spot syndrome virus envelope protein VP28 is involved in the systemic infection of shrimp. *Virology* 2001;285:228–33.
- [20] Chazal N, Gerlier D. Virus entry, assembly, budding, and membrane rafts. *Microbiol Mol Biol Rev* 2003;67:226–37.
- [21] Yi G, Wang Z, Qi Y, Yao L, Qian J, Hu L. VP28 of shrimp white spot syndrome virus is involved in the attachment and penetration into shrimp cells. *J Biochem Mol Biol* 2004;37:726–34.
- [22] Witteveldt J, Cifuentes C, Vlask JM, van Hulten MCW. Protection of *Penaeus monodon* against white spot syndrome virus by oral vaccination. *J Virol* 2004;78:2057–61.
- [23] Witteveldt J, Vlask JM, van Hulten MCW. Protection of *Penaeus monodon* against white spot syndrome virus using a WSSV subunit vaccine. *Fish Shellfish Immunol* 2004;16:571–9.
- [24] Vaseeharan B, Prem Anand T, Murugan T, Chen JC. Shrimp vaccination trials with the VP292 protein of white spot syndrome virus. *Lett Appl Microbiol* 2006;43:137–42.
- [25] Li LJ, Yuan JF, Cai CA, Gu WG, Shi ZL. Multiple envelope proteins are involved in white spot syndrome virus (WSSV) infection in crayfish. *Arch Virol* 2006;154:1–9.
- [26] Teunissen OSP, Faber R, Booms GHR, Latscha T, Boon JH. Influence of vaccination on vibriosis resistance of the giant black tiger shrimp *Penaeus monodon* (Fabricius). *Aquaculture* 1998;164:359–66.
- [27] Namikoshi A, Wu JL, Yamashita T, Nishizawa T, Nishioka T, Armoto M, et al. Vaccination trials with *Penaeus japonicus* to induce resistance to white spot syndrome virus. *Aquaculture* 2004;229:25–35.
- [28] Brown F. Inactivation of viruses by aziridines. *Vaccine* 2002;20:322–7.
- [29] Groseil C, Guerin P, Adamowicz P. Evaluation by polymerase chain reaction on the effect of betapropiolactone and binary ethyleneimine on DNA. *Biologicals* 1995;23:213–20.
- [30] Bahnmann HG. Binary ethyleneimine as an inactivant for foot and mouth disease virus and its application for vaccine production. *Arch Virol* 1975;47:47–56.
- [31] Bahnmann HG. Inactivation of viruses in serum with binary ethyleneimine. *J Clin Microbiol* 1976;2:209–10.
- [32] Aarthia D, Rao KA, Robinson R, Srinivasan VA. Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. *Biologicals* 2004;32:153–6.
- [33] Balasubramanian G, Sudhakaran R, Syed Musthaq, Sarathi M, SahulHameed AS. Studies on the inactivation of white spot syndrome virus (WSSV) of shrimp by physical and chemical treatment, and seaweed extracts tested in marine and freshwater animal models. *J Fish Dis* 2006;29:569–72.
- [34] Norihisa O, Toh Thy C, Yukio M, Beng Chu K, Palanisamy V. Examination for viral inactivation of WSSV (White Spot Syndrome Virus) isolated in Malaysia using black tiger prawn (*Penaeus monodon*). *Jpn Agric Res Q* 2006;40:93–7.
- [35] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970;227:680–5.
- [36] Amend DF. Potency testing of fish vaccines. In: Anderson DP, Hennessen W, editors. *Fish biologics: serodiagnostics and vaccines*. Basel: S. Karger; 1981. p. 447–54.

- [37] Bright Singh IS, Manjusha M, Somnath Pai S, Philip Rosamma. *Fenneropenaeus indicus* is protected from white spot disease by oral administration of inactivated white spot syndrome virus. *Dis Aquat Org* 2005;66:265–70.
- [38] George MR, Maharajan A, John KR, Jeyaseelan PMJ. Shrimps survive white spot syndrome virus challenge following treatment with *Vibrio* bacterin. *Indian J Exp Biol* 2006;44:63–7.
- [39] Habib M, Hussain I, Irshad H, Yang ZZ, Shuai JB, Chen N. Immunogenicity of formaldehyde and binary ethylenimine inactivated infectious bursal disease virus in broiler chicks. *J Zhejiang Univ Sci B* 2006;7:660–4.
- [40] Habib M, Hussain I, Fang WH, Rajput ZI, Yang ZZ, Irshad H. Inactivation of infectious bursal disease virus by binary ethylenimine and formalin. *J Zhejiang Univ Sci B* 2006;7:320–3.